-+ 0.00%
-+ 0.00%
-+ 0.00%

Formycon names Tezspire, Hemlibra as reference drugs for biosimilar candidates

PUBT·11/17/2026 05:32:02
Formycon names Tezspire, Hemlibra as reference drugs for biosimilar candidates
  • Formycon on Nov. 17, 2026, identified Tezspire and Hemlibra as reference drugs for two biosimilar candidates in early development.
  • FYB210 targets Tezspire, used for severe asthma, whose 2025 sales rose 50% to USD 1.9 billion.
  • FYB286 targets Hemlibra, which prevents bleeding in hemophilia A; sales rose 11% at constant currencies to CHF 4.8 billion.
  • Biocelys provides manufacturing infrastructure for FYB286, while Santo Biosimilar finances development; Formycon receives development fees and a low-double-digit share of future proceeds.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2436182_de) on November 17, 2026, and is solely responsible for the information contained therein.